Table 1

Sociodemographic and clinical characteristics of CML study population by compliance with the survey booklet (respondents vs nonrespondents)

VariableCompliance with the survey booklet
Nonrespondents (n = 26)Respondents (n = 422)Total (N = 448)
Sex, n (%)
    Female8 (30.8)172 (40.8)180 (40.2)
    Male18 (69.2)250 (59.2)268 (59.8)
Age at study entry, y
    18-392 (7.7)61 (14.4)63 (14.1)
    40-5913 (50.0)187 (44.3)200 (44.6)
    60-697 (26.9)91 (21.6)98 (21.9)
    ≥ 704 (15.4)83 (19.7)87 (19.4)
    Median545757
    Range22.0-85.819.4-86.819.4-86.8
Education, n (%)*
    Eighth grade or lessN/A194 (46.0)194 (46.0)
    High schoolN/A155 (36.7)155 (36.7)
    University degree or higherN/A70 (16.6)70 (16.6)
    MissingN/A3 (0.7)3 (0.7)
Marital status, n (%)*
    DivorcedN/A30 (7.1)30 (7.1)
    SingleN/A42 (10.0)42 (10.0)
    Married/living togetherN/A313 (74.2)313 (74.2)
    WidowN/A31 (7.3)31 (7.3)
    MissingN/A6 (1.4)6 (1.4)
Time from diagnosis, y
    Mean (SD)5.28 (1.56)5.32 (1.72)5.31 (1.71)
    Median5.15.15.1
    Range3.0-9.03.0-12.23.0-12.2
Duration of imatinib therapy, y
    Mean (SD)5.20 (1.52)5.13 (1.47)5.13 (1.48)
    Median5.155
    Range3.0-8.83.0-9.33.0-9.3
ECOG performance status, n (%)
    024 (92.3)286 (67.8)310 (69.2)
     ≥ 12 (7.7)136 (32.2)138 (30.8)
Sokal-risk at diagnosis, n (%)
    Low (< 0.8)12 (46.2)222 (52.6)234 (52.2)
    Intermediate (0.8-1.2)9 (34.6)140 (33.2)149 (33.3)
    High (> 1.2)4 (15.4)46 (10.9)50 (11.2)
    Missing1 (3.8)14 (3.3)15 (3.3)
Comorbidity at diagnosis, n (%)
    017 (65.4)269 (63.7)286 (63.8)
    ≥ 19 (34.6)153 (36.3)162 (36.2)
Initial imatinib dose, n (%)
    < 400 mg/d0 (0.0)16 (3.8)16 (3.6)
    400 mg/d25 (96.2)385 (91.2)410 (91.5)
    > 400 mg/d1 (3.8)21 (5.0)22 (4.9)
Current imatinib dose, n (%)
    < 400 mg/d1 (3.8)61 (14.5)62 (13.8)
    400 mg/d22 (84.7)327 (77.4)349 (77.9)
    > 400 mg/d3 (11.5)34 (8.1)37 (8.3)
Dose change during treatment, n (%)
    No16 (61.5)257 (60.9)273 (60.9)
    Yes (at least once)10 (38.5)165 (39.1)175 (39.1)
Time to first CCyR, y
    Mean (SD)0.90 (0.99)0.65 (0.62)0.66 (0.65)
    Median0.60.50.5
    Range0.0-5.20.1-6.30.0-6.3
  • CML indicates chronic myeloid leukemia; CCyR, complete cytogenetic response; SD, standard deviation; and N/A, not applicable.

  • * This was judged as N/A as this data was reported in the survey booklet.